CN117460714A - 用于癌症治疗的pcna抑制剂和egfr抑制剂 - Google Patents

用于癌症治疗的pcna抑制剂和egfr抑制剂 Download PDF

Info

Publication number
CN117460714A
CN117460714A CN202280039160.XA CN202280039160A CN117460714A CN 117460714 A CN117460714 A CN 117460714A CN 202280039160 A CN202280039160 A CN 202280039160A CN 117460714 A CN117460714 A CN 117460714A
Authority
CN
China
Prior art keywords
unsubstituted
substituted
independently
membered
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280039160.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·林奇曼
L·H·马尔卡斯
R·J·希基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of CN117460714A publication Critical patent/CN117460714A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280039160.XA 2021-04-30 2022-04-29 用于癌症治疗的pcna抑制剂和egfr抑制剂 Pending CN117460714A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182408P 2021-04-30 2021-04-30
US63/182,408 2021-04-30
PCT/US2022/026928 WO2022232509A1 (en) 2021-04-30 2022-04-29 Pcna inhibitors and egfr inhibitors for cancer treatment

Publications (1)

Publication Number Publication Date
CN117460714A true CN117460714A (zh) 2024-01-26

Family

ID=83847341

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280039160.XA Pending CN117460714A (zh) 2021-04-30 2022-04-29 用于癌症治疗的pcna抑制剂和egfr抑制剂

Country Status (11)

Country Link
US (1) US20240245634A1 (https=)
EP (1) EP4330224A4 (https=)
JP (1) JP2024516828A (https=)
KR (1) KR20240004548A (https=)
CN (1) CN117460714A (https=)
AU (1) AU2022264802A1 (https=)
BR (1) BR112023022530A2 (https=)
CA (1) CA3217330A1 (https=)
IL (1) IL307281A (https=)
MX (1) MX2023012744A (https=)
WO (1) WO2022232509A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118546074A (zh) * 2024-05-27 2024-08-27 安徽贝克制药股份有限公司 一种氘代增殖细胞核抗原抑制剂及其制备方法和其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054318A1 (en) * 2023-09-06 2025-03-13 City Of Hope Pcna inhibitors and uses thereof
CN120097860A (zh) * 2023-12-05 2025-06-06 杜心赟 增殖细胞核抗原抑制剂、其制备方法、其中间体、其药物组合物和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348512A (zh) * 2015-09-17 2018-07-31 希望之城 Pcna抑制剂
US20200222407A1 (en) * 2018-11-19 2020-07-16 Amgen Inc. Combination therapy including a kras g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348512A (zh) * 2015-09-17 2018-07-31 希望之城 Pcna抑制剂
US20200222407A1 (en) * 2018-11-19 2020-07-16 Amgen Inc. Combination therapy including a kras g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NANNAN WANG ET AL.: "Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer", 《ONCOLOGY REPORTS》, vol. 41, 17 October 2018 (2018-10-17), pages 77 - 86 *
WEN QI CAI ET AL.: "The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells", 《FRONTIERS IN ONCOLOGY》, vol. 10, 24 July 2020 (2020-07-24), pages 1249 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118546074A (zh) * 2024-05-27 2024-08-27 安徽贝克制药股份有限公司 一种氘代增殖细胞核抗原抑制剂及其制备方法和其应用

Also Published As

Publication number Publication date
CA3217330A1 (en) 2022-11-03
JP2024516828A (ja) 2024-04-17
AU2022264802A1 (en) 2023-10-12
EP4330224A4 (en) 2025-03-19
WO2022232509A1 (en) 2022-11-03
EP4330224A1 (en) 2024-03-06
MX2023012744A (es) 2024-01-05
IL307281A (en) 2023-11-01
US20240245634A1 (en) 2024-07-25
BR112023022530A2 (pt) 2024-01-16
KR20240004548A (ko) 2024-01-11

Similar Documents

Publication Publication Date Title
CN115803327B (zh) Cdk抑制剂
JP2023512040A (ja) 化合物及びその使用
CN117460714A (zh) 用于癌症治疗的pcna抑制剂和egfr抑制剂
CN119954725A (zh) Tead抑制剂和其用途
EP3349754B1 (en) Pcna inhibitors
JP6933644B2 (ja) アンドロゲン受容体拮抗薬
TW202339729A (zh) 使用ptpn11抑制劑與kras g12c抑制劑之組合療法
JP2018510134A (ja) 組合せがん治療法
Konar et al. Synthesis and clinical development of palbociclib: An overview
CN115381832A (zh) 癌症的治疗
TWI763372B (zh) 用於癌症治療之ＴＧＦβ抑制劑及ＣＤＫ抑制劑之組合
EP3999056B1 (en) Pharmaceutical combination and its use in the prevention and treatment of cancer
CN118574616A (zh) 使用ptpn11抑制剂和egfr抑制剂的组合疗法
AU2018397483A1 (en) Heterocycle compounds as Tyro3, Axl and Mertk (TAM) family of receptor tyrosine kinase inhibitors
CN108348519A (zh) 经氯苯取代的氮杂芳基化合物
EA052352B1 (ru) Ингибиторы pcna и ингибиторы egfr для лечения рака
CN116546986A (zh) Alk-5抑制剂及其用途
HK40083903A (en) Treatment of cancer
WO2017205611A1 (en) Estrogen receptor modulator combinations
EP4638443A1 (en) Transient receptor potential vanilloid 6 inhibitors
JP2023513016A (ja) Ｎｅｋ２阻害剤としてのアミノピリミジニルアミノベンゾニトリル誘導体
CN117355304A (zh) Alk-5抑制剂及其用途
BR112018005331B1 (pt) Inibidores de pcna
HK1258793B (en) Pcna inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination